South Africa anticoagulant market is projected to register a CAGR of 5.1% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
South Africa Anticoagulant Market By Drug Class (Vitamin K Antagonist (Warfarin), Non-VKA Oral Anticoagulants (NOACS), Heparin & LMWH, Thrombin Inhibitors (Dabigatran)), Therapeutic Areas (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Atrial Fibrillation, Heart Attack, Stroke, Unstable Angina, Hip Or Knee Replacement Surgery, Others), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy, Others)- Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of South Africa anticoagulant market are:

• Rising prevalence of venous thromboembolism and pulmonary embolism
• Number of patients requiring lifelong anticoagulation therapy
Market Players:

The key market players for South Africa anticoagulant market are listed below:

• Sanofi
• Fresenius Kabi AG (A subsidiary of Fresenius SE & Co KGaA)
• Aspen Holdings
• Cipla Inc.
• Bayer AG
• Pfizer Inc.
• Boehringer Ingelheim International GmbH
• Adcock Ingram